Last reviewed · How we verify
NCT05365542: ClotSigns
Anticoagulation in Chronic Hemodialysis Patients Versus Hemodialyzer Fiber Patency, Bleedings and Quality of Life
trial testing Hemodialyzer scanning in Blood Coagulation in 70 participants. Completed in 31 December 2022.
10 July 2022
Quick facts
| Lead sponsor | University Hospital, Ghent |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 70 |
| Start date | 27 April 2022 |
| Primary completion | 10 July 2022 |
| Estimated completion | 31 December 2022 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- Hemodialyzer scanning
- Bleeding Questionnaires
- Quality of life questionnaire
- Visual inspection of the limbs
Conditions studied
- Blood Coagulation — all drugs for Blood Coagulation →
Sponsor
University Hospital, Ghent
Who can join
18 and older, any sex, with Blood Coagulation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Stable chronic hemodialysis patients are included in this observational study. After a midweek dialysis (test moment 1), the hemodialyzer is dried and scanned in a micro Computed Tomography scanner to quantify the number of patent fibers. All dialysis parameters are collected as well as the anticoagulation dose. During the same session, patients are asked about their bleeding and quality of life status. Four (test moment 2) respectively eight weeks later (test moment 3), patients are asked again for their bleeding and quality of life status using validated questionnaires.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Association between anticoagulation strategy and quality of life in chronic hemodialysis patients.
Eloot S, Vanommeslaeghe F, Josipovic I, Boone M, et al · · 2023 · cited 3× · PMID 37704691 · DOI 10.1038/s41598-023-42069-2
Verify or expand the search:
- PubMed search for NCT05365542
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University Hospital, Ghent trials
Trials by the same sponsor.
- NCT07584486 — Development of a New Simplified Tool to Predict LNPCPs Histology and Assess the Risk of Submucosal Invasive Cancer. The · NA · not yet recruiting
- NCT07327450 — Coaching Doctors and Nurses to Improve Ethical Decision-making in Team · NA · not yet recruiting
- NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
- NCT07387328 — Validation of New sEMG Electrode Placement Guidelines for the Triceps Surae in Post-stroke Individuals. · not yet recruiting
- NCT07237399 — Percutaneous Thermo-ablation for the Treatment of Prostate Cancer Oligometastatasis (TA-P-OLIM) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05365542 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Ghent
- Last refreshed: 6 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05365542.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing